151751-Najiba-Chargi

305 Systemic therapy: skeletal muscle mass and oropharyngeal carcinoma Table 3. Univariate and multivariate Cox regression analysis: disease-free survival Variable Univariate analysis Multivariate analysis (*) Model 1 Model 2 HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value Low SMM 1.81 0.95-3.45 0.07 1.41 0.60-3.33 0.44 - - - Sarcopenic obesity 2.03 0.73-5.68 0.18 - - - 3.49 1.08-11.27 0.037* HPV risk group Low Intermediate High Ref. 1.76 4.85 0.54-5.77 1.89-12.42 0.35 0.001** Ref. 1.71 4.06 0.51-5.72 1.52-10.84 0.38 0.005** Ref. 1.93 4.32 0.59-6.36 1.64-11.38 0.28 0.003** Age (years) 0.99 0.96-1.02 0.57 BMI (kg/m 2 ) 20-24.9 <20 25-30 ≥30 Ref. 1.05 0.36 0.96 0.48-2.29 0.14-0.88 0.43-2.15 0.90 0.03* 0.92 Ref. 0.75 0.541.30 0.34-1.64 0.21-1.42 0.47-3.56 0.75 0.21 0.62 Ref. 0.78 0.39 0.80 0.36-1.72 0.14-1.05 0.33-1.94 0.54 0.06 0.62 Weight loss 6 months prior to diagnosis (%) 0 ≤ 10% > 10% Ref. 1.46 1.33 0.73-2.91 0.52-3.45 0.29 0.55 ACE-27 score Non Mild Moderate Severe Ref. 1.02 1.42 1.14 0.45-2.31 0.68-2.97 0.40-3.25 0.97 0.36 0.80 TNM stage I II III IV Ref. 0.70 1.19 1.13 0.21-2.28 0.39-3.64 0.43-2.94 0.55 0.76 0.81 Legend: **. Correlation is significant at the 0.01 level (2-tailed),*. Correlation is significant at the 0.05 level (2-tailed), (*) Model 1 includes the variables; low SMM, HPV-related risk group, age, BMI, percentage weight loss 6 months prior to diagnosis , ACE-27 score and TNM-stage. Model 2 includes sarcopenic obesity, HPV-related risk group, age, BMI, percentage weight loss6 months prior to diagnosis, ACE-27 score and TNM-stage. 16